Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET. A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation. About Blueprint Medicine

-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy -- -- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course --  -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor -- CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC)

-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass., Feb. 13, 2025 /PRNewswire/ -- Blueprint Medici

Morgan Stanley resumed coverage of Blueprint Medicines with a rating of Equal-Weight and set a new price target of $100.00

Wolfe Research initiated coverage of Blueprint Medicines with a rating of Outperform

Jefferies initiated coverage of Blueprint Medicines with a rating of Buy and set a new price target of $135.00

4 - Blueprint Medicines Corp (0001597264) (Issuer)

4 - Blueprint Medicines Corp (0001597264) (Issuer)

4 - Blueprint Medicines Corp (0001597264) (Issuer)

S-8 - Blueprint Medicines Corp (0001597264) (Filer)

10-K - Blueprint Medicines Corp (0001597264) (Filer)

8-K - Blueprint Medicines Corp (0001597264) (Filer)

-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa

Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

-- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos

-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass., Feb. 13, 2025 /PRNewswire/ -- Blueprint Medici

CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 13, 2025, to report its fourth quarter and full year 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 349846. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicine

-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- --  On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance. "With another strong quarter of AYVAKIT revenue perform

SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)